How this therapy could help:
The memory loss and functional decline of AD have been linked to abnormal protein deposits that build up in the brain. Among those proteins are amyloid and tau. Deposits of abnormal tau, so-called neurofibrillary tangles, form in the neurons and are linked to increasing impairment and loss of brain cells associated both with AD and with other neurodegenerative diseases, known as tauopathies, such as progressive supranuclear palsy and frontotemporal dementia. BIIB092 is an antibody targeting extracellular tau and may reduce the spreading of tau from one cell to the next, potentially slowing the progress of the disease.
Disclaimer: The views, opinions, statements and claims expressed in articles, studies, surveys and/or publications in connection with various products offered for sale by Bio-Tech Pharmacal, Inc. contained in this web site are those only of the author(s) of such views, opinions, statements and/or claims, none of which Bio-Tech Pharmacal, Inc. has endorsed or adopted and none of which have been evaluated by the . Food and Drug Administration. Bio-Tech Pharmacal, Inc.'s products are not intended for use in the diagnosis, cure, mitigation, treatment, or prevention of any disease.
In conjunction with the corporate name change, we will also be changing our NASDAQ ticker symbol from ISIS to IONS. The new ticker symbol will become effective at the open of the market on December 22, 2015. In addition, we will have a new website address: , a new email domain: @ and a new Twitter account: @ionispharma. Visitors to our old website will be redirected to our new site and email sent to our old email addresses will still be delivered correctly. Our company address and phone numbers will not change.